PriceSensitive

Datametrex and Transpharm Canada to process COVID-19 kits

Technology
TSXV:DM
21 May 2020 14:01 (EDT)

Datametrex AI (TSXV:DM) has signed a Strategic Partnership and Development Agreement with Transpharm Canada for testing COVID-19 kits.

Under the agreement, Transpharm will provide access to its 25,000 square foot testing facility in Toronto, Ontario. The companies will use the facility to process COVID-19 testing kits which Datametrex has in its portfolio.

While Datametrex will provide the test kits, Transpharm will deliver all other services under the agreement. These include the collection of specimens, transport of specimens, and processing the test results.

This will involve developing a delivery procedure which ensures the safe transport of samples. The company will develop protocols which guarantees tubes are tightly sealed and shipped at safe temperature levels.

In addition, Transpharm will design, engineer, and develop a fully integrated suite of testing systems for the endeavour. The company’s laboratory capacity can currently process 2,304 nucleic acid COVID-19 detection kits every 24 hours. 

Datametrex identified a need for the agreement, after realising that most public and private corporations are not equipped to process test kits on their own. Since the onset of COVID-19, the company has formed relationships with four test kit manufacturers in South Korea.

Datametrex’s CEO, Marshall Gunter, commented on the agreement with Transpharm.

“By participating in this project, Datametrex reaffirms its commitment to helping its customers, shareholders, families, and the Canadian public. 

“This project hopes to aid in the reopening of businesses, travel, places of worship, community spaces, and social and cultural events in a safe and economic way,” he said.

Datametrex AI (DM) is up 4.00 per cent and is trading at C$0.13 per share at 1:46pm EDT.

Related News